Citations 11
Racial and ethnic differences in clinical outcomes among patients with multiple myeloma treated with CAR T-cell therapy
Peres, Lauren C. , Oswald, Laura B. , Dillard, Christen , Avila, Gabriel De, Nishihori, Taiga , Blue, Brandon , Freeman, Ciara L. , Alsina, Melissa , Puglianini, Omar Castañeda , Shune, Leyla , Sborov, Douglas W. , Wagner, Charlotte B , Hashmi, Hamza , Davis, James A. , Badros, Ashraf , Simmons, Gary , Kalariya, Nilesh, Ferreri, Christopher J. , Anderson, Larry D. , Afrough, Aimaz , Liu, Lawrence , Voorhees, Peter M. , Khouri, Jack , Sidana, Surbhi , Patel, Krina K. , Dillard, Christen M , Castaneda Puglianini, Omar , Sborov, Douglas W , Wagner, Charlotte , Dima, Danai , Hashmi, Hamza , Davis, James A , Kocoglu, Mehmet H , Badros, Ashraf Z , Ferreri, Christopher , Anderson, Larry D , Kaur, Gurbakhash , Liu, Lawrence , Voorhees, Peter , Khouri, Jack , McGuirk, Joseph , Sidana, Surbhi , Patel, Krina , Nishihori, Taiga , Locke, Frederick L. , Dima, Danai , Kocoglu, Mehmet H. , Atrash, Shebli , Kaur, Gurbakhash , Lin, Yi , Nadeem, Omar , McGuirk, Joseph P. , Hansen, Doris K.
Blood Advances | October 19, 2023 | Volume: 8 | Issue: 1 | Pages: 251-259
10.1182/bloodadvances.2023010894
Abstract Idecabtagene vicleucel (ide-cel) was the first chimeric antigen receptor T-cell therapy to gain US Food and Drug Administration approval for patients with relapsed/refractory multiple myeloma (RRMM). The clinical outcomes of standard of care (SOC) ide-cel in racially and ethnically diverse populations have been understudied. This study pooled data from 207 patients with RRMM (28% patients of racial and ethnic minority groups) treated with SOC ide-cel across 11 institutions to examine racial and ethnic differences in the incidence of toxicities and adverse events, response to ide-cel, and survival. This study included 22 (11%) Hispanic, 36 (17%) non-Hispanic Black, and 149 (72%) non-Hispanic White patients with RRMM. Compared with Hispanic and non-Hispanic White patients, non-Hispanic Black patients had higher median levels of C-reactive protein (1.0, 0.8, and 3.5 mg/dL, respectively; P = .02) and baseline ferritin (362.0 vs 307.0 vs 680.5, respectively; P = .08) and were more likely to develop cytokine release syndrome (77%, 85%, and 97%, respectively; P = .04). Although best overall response rate was lower among Hispanic patients (59%) than among non-Hispanic Black (86%) and White patients (86%; P = .01), there were no racial and ethnic differences in progression-free or overall survival. We provide, to our knowledge, the first and largest investigation of clinical outcomes of SOC ide-cel by race and ethnicity. Despite differences in safety and response to ide-cel, our findings encourage the use of ide-cel in all patients with RRMM. These findings should be confirmed in larger samples of diverse patients with RRMM, with longer follow-up time.